Using Methylene Blue or Mitoquinone to Improve Skeletal Aging | Aging-US



April 2, 2024

  • Share
  • Aging-US published this trending research paper on March 25, 2024, in Volume 16, Issue 6, entitled, “Targeting mitochondrial dysfunction using methylene blue or mitoquinone to improve skeletal aging" by researchers from the Department of Molecular Pathobiology, David B. Kriser Dental Center, New York University College of Dentistry, New York, NY; Department of Biomedical Engineering, City College of New York, New York, NY; Department of Epidemiology and Health Promotion, David B. Kriser Dental Center, New York University College of Dentistry, New York, NY; Jackson Aging Center, Nathan Shock Center for Excellence in the Basic Biology of Aging, The Jackson’s Laboratories, Aging Center, Bar Harbor, ME; Department of Pathology and Geriatrics Center, University of Michigan, Ann Arbor, MI; The Jackson Laboratory, Bar Harbor, ME; Geriatric Research, Education and Clinical Center and Research Service, South Texas Veterans Health Care System, San Antonio, TX; Department of Pharmacology, Barshop Institute for Longevity and Aging Studies, The University of Texas Health Science Center, San Antonio, TX. DOI - Corresponding author - Shoshana Yakar - Abstract Methylene blue (MB) is a well-established antioxidant that has been shown to improve mitochondrial function in both in vitro and in vivo settings. Mitoquinone (MitoQ) is a selective antioxidant that specifically targets mitochondria and effectively reduces the accumulation of reactive oxygen species. To investigate the effect of long-term administration of MB on skeletal morphology, we administered MB to aged (18 months old) female C57BL/J6 mice, as well as to adult male and female mice with a genetically diverse background (UM-HET3). Additionally, we used MitoQ as an alternative approach to target mitochondrial oxidative stress during aging in adult female and male UM-HET3 mice. Although we observed some beneficial effects of MB and MitoQ in vitro, the administration of these compounds in vivo did not alter the progression of age-induced bone loss. Specifically, treating 18-month-old female mice with MB for 6 or 12 months did not have an effect on age-related bone loss. Similarly, long-term treatment with MB from 7 to 22 months or with MitoQ from 4 to 22 months of age did not affect the morphology of cortical bone at the mid-diaphysis of the femur, trabecular bone at the distal-metaphysis of the femur, or trabecular bone at the lumbar vertebra-5 in UM-HET3 mice. Based on our findings, it appears that long-term treatment with MB or MitoQ alone, as a means to reduce skeletal oxidative stress, is insufficient to inhibit age-associated bone loss. This supports the notion that interventions solely with antioxidants may not provide adequate protection against skeletal aging. Sign up for free Altmetric alerts about this article - Subscribe for free publication alerts from Aging - Keywords - aging, methylene blue, mitoquinone, bone, micro-CT, antioxidants About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at​​ and connect with us: Facebook - X - Instagram - YouTube - LinkedIn - Pinterest - Spotify - Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

    Cell ScienceMolecular Biology

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.